To elucidate the mechanisms by which TRIM32 plays a cardioprotective role in cardiac hypertrophy and heart failure, we next examined the status of the MAPK and Akt signalling pathways, which are known to be involved in pathological cardiac hypertrophy [26–29]. Here, TRIM32 is linked to cardiac hypertrophy.